TARA Protara Therapeutics, Inc.
Price Chart
Executive Summary
JP Morgan reiterated its Overweight rating on TARA with a $26 price target on May 14, 2026, part of a broader cluster of bullish initiations and maintains from six firms. Consensus is overwhelmingly positive: 13 of 14 analysts rate Buy or Strong Buy, with a mean target of $26 — implying ~391% upside from the current $5.30. JP Morgan’s track record is solid at 55% accuracy on 5,703 calls with an average return of 5.6%. No analyst downgrades have occurred in the past 30 days, though EPS revisions have been mixed (3 down, 1 up in the last month). Institutional accumulation is extremely strong: Vanguard, Two Sigma, FMR, Morgan Stanley, and Bank of America all added positions, with FMR nearly 10x its stake. However, insider selling by CFO Zummo Jacqueline totaling ~$125k over two trades in April 2026 introduces a divergence signal. The combination of compelling valuation, strong institutional inflows, and near-unanimous analyst support suggests a bullish bias, but the insider activity and low base analyst score (2/7) warrant a measured approach.
Impact Score
Consensus & Targets
92.9% Buy-side consensus: 3 Strong Buy, 10 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 14 analysts. The sole Hold is a contrarian view; the overwhelming majority sees significant upside.
Mean and median price target $26.00; high $30.00 (LifeSci Capital), low $24.00 (Piper Sandler). Current price $5.30 implies ~391% upside to the mean. JP Morgan's $26 target is in line with consensus.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-14 | JP Morgan | maintain | Overweight | $26.00 |
| 2026-04-29 | HC Wainwright & Co. | maintain | Buy | $27.00 |
| 2026-03-04 | JP Morgan | initiate | Overweight | — |
| 2026-02-10 | HC Wainwright & Co. | reiterate | Buy | $23.00 |
| 2026-01-07 | Piper Sandler | initiate | Overweight | $24.00 |
| 2025-12-03 | HC Wainwright & Co. | reiterate | Buy | $23.00 |
| 2025-11-19 | HC Wainwright & Co. | reiterate | Buy | $23.00 |
| 2025-05-22 | Jones Trading | initiate | Buy | $21.00 |
| 2025-04-28 | HC Wainwright & Co. | reiterate | Buy | $23.00 |
| 2025-04-16 | Scotiabank | initiate | Sector Outperform | $12.00 |
No upgrades or downgrades in the last 30 days. EPS estimates have seen mixed revisions: both +1q and 0q EPS averages improved (losses narrowed) over the past 30 days, but the number of downward revisions (3) exceeded upward revisions (1), indicating lingering skepticism.
Firm Track Record — JP Morgan
JP Morgan accuracy: 55% on 5703 calls | avg return: 5.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 2 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Oppenheimer | 50% | 1/2 | 4.5% | below average |
| HC Wainwright & Co. | 33% | 3/9 | -3.2% | below average |
JP Morgan has a 55.5% accuracy rate on 5,703 scored calls with an average return of 5.6%. Other covering firms (Oppenheimer, HC Wainwright) have very small sample sizes (<10 calls) and below-average performance, making JP Morgan the most credible analyst on the name.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $-0.35 | $-0.38 — $-0.32 | $0.00 | ↑1 ↓0 |
| 0q | $-0.33 | $-0.35 — $-0.31 | $0.00 | ↑1 ↓0 |
| +1y | $-1.35 | $-1.94 — $-0.40 | $48.3M | ↑1 ↓0 |
| 0y | $-1.34 | $-1.45 — $-1.24 | $0.00 | ↑1 ↓0 |
Cross-Platform Signals
Insider trading is bearish: CFO Zummo Jacqueline sold ~$125k in two April trades with no insider buys. However, institutional buying is extraordinarily strong: Vanguard added 25.6%, Two Sigma 67%, Morgan Stanley 61.5%, Bank of America 174.8%, and FMR nearly 850%. This divergence — insiders selling while institutions load up — suggests institutional conviction outweighs routine insider liquidity sales.
Actionable Insight
Load up on TARA near $5.30. The 391% upside to consensus targets, combined with aggressive institutional accumulation, overrides weak insider sales. Use any dip from insider-driven noise as an entry point.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
18d ago
|
EFFECT
| $4.80 $4.34 | ▲ +9.58% | ▲ +10.80% | $3.90 (+18.75%) |
|
May 16, 2026
27d ago
|
ANALYST-UPGRADE
| $6.20 $5.60 | ▼ −9.68% | ▼ −8.34% | $3.90 (−37.10%) |
|
May 15, 2026
29d ago
|
Press Release
| $5.10 $4.92 | ▼ −3.53% | ▼ −4.49% | $3.90 (−23.53%) |
|
May 13, 2026
4w ago
|
8-K
| $5.20 $4.34 | ▼ −16.54% | ▼ −15.38% | $3.90 (−25.00%) |
|
May 13, 2026
4w ago
|
Press Release
| $5.20 $4.34 | ▼ −16.54% | ▼ −15.38% | $3.90 (−25.00%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $5.17 $5.66 | ▲ +9.48% | ▲ +6.37% | $3.90 (−24.56%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access